연구동향 분석

Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes

변지영 이윤정 김영훈 김세형 이충민 배정우 장춘곤 이석용 최창익 2018년

논문상세정보
    • 저자 변지영 이윤정 김영훈 김세형 이충민 배정우 장춘곤 이석용 최창익
    • 제어번호 106053014
    • 학술지명 Archives of Pharmacal Research
    • 권호사항 Vol. 41 No. 5 [ 2018 ]
    • 발행처 대한약학회
    • 발행처 URL http://www.psk.or.kr
    • 자료유형 학술저널
    • 수록면 564-570 ( 7쪽)
    • 언어 English
    • 출판년도 2018
    • 등재정보 KCI등재
    • 소장기관 부산대학교 중앙도서관 숙명여자대학교 중앙도서관 영남대학교 중앙도서관 영남대학교 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관 중앙대학교 서울캠퍼스 중앙도서관
    • 판매처
    유사주제 논문( 0)
인용/피인용

' Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes' 의 참고문헌

  • Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype
    Choi CI [2012]
  • Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite
    Zhang X [2009]
  • Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine
    Zhang QY [2007]
  • Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
    Taguchi K [1998]
  • Power and sample size calculations for studies involving linear regression
    Dupont WD [1998]
  • Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy
  • Pharmacokinetics and pharmacodynamics of tamsulosin in its modifiedrelease and oral controlled absorption system formulations
  • Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers
    Chu N [2015]
  • Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms
    Chaudhry SR [2014]
  • PCR-based genotyping for duplicated and deleted CYP2D6 genes
    Johansson I [1996]
  • Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression
    Pinto AG [2005]
  • Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs
    Hirota T [2013]
  • Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes
    Kamimura H [1998]
  • Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
    Johansson I [1994]
  • Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre Korean study
    Park CH [2004]
  • Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia
    Li NC [2003]
  • Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites
    변지영 [2015]
  • Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes
    Taguchi K [1997]
  • Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin
    Troost J [2011]
  • Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
  • Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite
  • Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites
    김미정 [2018]
  • Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers
    Li H [2015]
  • Effect of concomitant administration of cimetidine hydrochloride on the pharmacokinetic and safety profile of tamsulosin hydrochloride 0.4 mg in healthy subjects
    Miyazawa Y [2002]
  • Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors
  • Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate
    Michel MC [1998]
  • Drug interactions with calcium channel blockers: possible involvement of metaboliteintermediate complexation with CYP3A
    Ma B [2000]
  • Dose of midazolam should be reduced during diltiazem and verapamil treatments
    Backman JT [1994]
  • Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling
  • Diltiazem: a review of its pharmacological properties and therapeutic efficacy
    Chaffman M [1985]
  • Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients
    Bleck JS [1996]
  • Diltiazem enhances the effects of triazolam by inhibiting its metabolism
    Varhe A [1996]
  • Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique
  • Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4
    Molden E [2002]
  • Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients
    Lee E [2003]
  • Clinical application of pharmacogenomics
    Ma JD [2012]
  • CYP2D6 polymorphism in a Mexican American population
    Mendoza R [2001]
  • CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells
    Molden E [2000]
  • Boehringer Ingelheim Pharmaceuticals Incorporated, Ridgefield
  • Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate
    Michel MC [2006]
  • Absorption, metabolism and excretion of tamsulosin hydrochloride in man
    Soeishi Y [1996]